BSF Enterprise (LSE:BSFA) said the public sale of its Enfin Levé T‑Rex Leather™ handbag proved its Advanced Tissue Engineering Platform's structural capability and, supported by a recently announced £1 million interest‑free convertible loan note from Indigo Capital, the group is funded to scale operations.
The funding will be prioritised to scale its three subsidiaries in the stated order: Lab‑Grown Leather (LGL) to commercialise tannable skin and B2B assessment pipelines, 3D Bio‑Tissues (3DBT) to expand sales of City‑Mix™ and CytoBoost™, and Kerato to progress veterinary and clinical corneal repair milestones.
Public bidding in Paris reached €150,000, fell short of the company's historic reserve, and the handbag has been withdrawn from the auction and moved into a private‑sale process targeting interested parties, institutional collectors, museums and high‑net‑worth individuals.
The auction exhibition has accelerated inbound technical dialogues with multi‑billion‑dollar contacts, the company said, including a global sportswear leader evaluating performance footwear applications and a tier‑one automotive manufacturer assessing scalable upholstery use.
BSF emphasised its commercial model relies on eventual high‑volume industrial supply, licensing and the sale of automated bioreactor infrastructure rather than the sale of singular luxury accessories, and said City‑Mix™ and CytoBoost™ revenues provide parallel insulation.
"While the public auction bidding didn't meet our historic reserve, the commercial validation we required has been emphatically achieved," said Dr Che Connon, CEO.
The handbag will now progress into private sale while technical evaluations with automotive and footwear partners continue.
